1. Home
  2. MTX vs BEAM Comparison

MTX vs BEAM Comparison

Compare MTX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTX
  • BEAM
  • Stock Information
  • Founded
  • MTX 1968
  • BEAM 2017
  • Country
  • MTX United States
  • BEAM United States
  • Employees
  • MTX N/A
  • BEAM N/A
  • Industry
  • MTX Major Chemicals
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MTX Industrials
  • BEAM Health Care
  • Exchange
  • MTX Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • MTX 1.7B
  • BEAM 1.7B
  • IPO Year
  • MTX 1992
  • BEAM 2020
  • Fundamental
  • Price
  • MTX $61.69
  • BEAM $17.46
  • Analyst Decision
  • MTX Strong Buy
  • BEAM Strong Buy
  • Analyst Count
  • MTX 2
  • BEAM 10
  • Target Price
  • MTX $82.00
  • BEAM $48.56
  • AVG Volume (30 Days)
  • MTX 285.4K
  • BEAM 2.4M
  • Earning Date
  • MTX 07-24-2025
  • BEAM 08-05-2025
  • Dividend Yield
  • MTX 0.71%
  • BEAM N/A
  • EPS Growth
  • MTX N/A
  • BEAM N/A
  • EPS
  • MTX 0.06
  • BEAM N/A
  • Revenue
  • MTX $2,063,500,000.00
  • BEAM $60,272,000.00
  • Revenue This Year
  • MTX N/A
  • BEAM N/A
  • Revenue Next Year
  • MTX $4.53
  • BEAM $17.18
  • P/E Ratio
  • MTX $992.48
  • BEAM N/A
  • Revenue Growth
  • MTX N/A
  • BEAM N/A
  • 52 Week Low
  • MTX $49.54
  • BEAM $13.53
  • 52 Week High
  • MTX $86.49
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • MTX 61.11
  • BEAM 39.16
  • Support Level
  • MTX $57.67
  • BEAM $16.65
  • Resistance Level
  • MTX $63.32
  • BEAM $21.40
  • Average True Range (ATR)
  • MTX 1.63
  • BEAM 1.00
  • MACD
  • MTX 0.38
  • BEAM -0.35
  • Stochastic Oscillator
  • MTX 65.51
  • BEAM 13.89

About MTX Minerals Technologies Inc.

Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of our customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve our customers' manufacturing processes and projects. The majority of revenue comes from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: